AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil.

Details on AbCellera’s oral presentation at IMS are as follows:

Title: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms

Abstract ID: 16836

Session: Symptoms of Menopause 1

Date and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3

Location: Aruba 1, Windsor Oceânico Hotel and Congress Center

AbCellera will present efficacy and safety data from its Phase 2 trial in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS).